Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, Sapio Sciences, BioMicro Systems

Illumina last week announced that a 12-sample Infinium DNA Methylation BeadChip for use in epigenetic research will become available in the first quarter of next year.
Using the array, researchers can assay approximately 27,000 CpG sites per sample, covering more than 14,000 well-annotated genes with single CpG resolution, Illumina said.
The company said that content for the panel was derived from genes described in the National Center for Biotechnology Information’s Consensus Coding Sequence database. It features a core set of protein-coding regions as well as more than 1,000 cancer-related genes and 200 CpG sites located within CpG islands found in promoter regions of microRNA genes.
Last week Illumina also introduced its MicroRNA Assay for Gene Expression profiling.
The company said that the assay is priced at $95 per sample and was developed with content from the Sanger Center’s miRBase sequence database. Illumina first discussed its miRNA assay last month (see BAN 9/18/2007).

Sapio Sciences has released a copy number variation analysis tool to support Illumina’s Infinium arrays.
The Exemplar Analytics 4.0.8 tool provides CNV analysis and also supports all Illumina DNA analysis beadchips. Additional features include principal components analysis for admixture corrections; allele counting of hemizygous SNPs; and an update of the annotations database with current information from dBSNP, Entrez Gene and Gene Ontology.

BioMicro Systems last week launched its MAUI Wash System for microarray processing following hybridization.

The system automatically washes and dries up to 12 microarray slides simultaneously, reducing the variability of results obtained compared to manual processing, according to the company. The instrument fits in the workflow of mid- to high-throughput laboratories and ideally works in conjunction with BioMicro’s MAUI 12-Bay System, the company said.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.